- The FDA approves Luminex's (NASDAQ:LMNX) ARIES molecular diagnostics system. The product features internal barcode scanning to minimize operator errors and two independent modules that each support up to six cassettes to accommodate STAT and batch testing.
- The company's test for Herpes Simplex Virus 1 and 2 was also approved.
- The formal market introduction of the system will happen at the Association for Molecular Pathology annual meeting in Austin, TX, November 4-7.
- Management will host a conference call this morning at 8:30 am ET to discuss the products.